Clinical data
AHFS/ Monograph
MedlinePlus a607008
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
Nasal inhalation
ATC code R01AD13 (WHO) R03BA08 (WHO)
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Synonyms (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
CAS Number 126544-47-6 N
PubChem (CID) 6918155
DrugBank DB01410 YesY
ChemSpider 5293368 YesY
UNII S59502J185 YesY
KEGG D01703 YesY
Chemical and physical data
Formula C32H44O7
Molar mass 540.688 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand names Alvesco for asthma and Omnaris, Omniair, and Zetonna for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside of the US are ongoing.[1] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[2] Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[3]

See also


  1. "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Archived from the original on February 2, 2009. Retrieved 2009-07-30.
  2. "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies.". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30.
  3. Mutch, Elaine; Nave, Ruediger; McCracken, Nigel; Zech, Karl; Williams, Faith M. (2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology. 73 (10): 1657–64. doi:10.1016/j.bcp.2007.01.031. PMID 17331475.

Further reading

This article is issued from Wikipedia - version of the 9/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.